Axsome Therapeutics Inc

AXSMNASDAQ · USD
132.37USD+2.57 (+1.98%)
317

Axsome Therapeutics Inc (AXSM) Option Chain

Axsome Therapeutics Inc trades at $132.37, up 1.98%, with an IV Rank of 87.70%. This is high versus the past year, and the company carries a market cap of $6,827M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $130.00 strike shows calls at $5.20 / $8.10 and puts at $4.80 / $7.40, both carrying about $5.19 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $165.00 calls, at 120 contracts, and the $165.00 puts, at 8, as of Nov 5, 2026.

Read more

Tracking the AXSM option chain helps you see every strike and expiry on Axsome Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of AXSM options activity at a glance. Use our scanner to monitor the AXSM option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For AXSM stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where AXSM options are being actively traded, and where they are not.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
26.85280-0.3212.3710.3013.80120.00-7.551.602.800.002.20127673.15
39.262101.737.377.7010.50125.00-3.702.754.600.003.6837260.74
52.331804.282.375.208.10130.00+0.154.807.400.006.1077047.67
64.703914.800.003.506.10135.00+4.017.6010.402.636.37716535.30
75.31210782.900.001.704.10140.00+7.8611.3014.507.635.2707224.69

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank87.70% High
  • Market cap (M$)6,827
  • 52 weeks high-50.11%
  • 52 weeks low5.53%
  • Analyst recommendationStrong Buy
    1.13
  • Target price$265.86
    109.91% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-02
  • P/E—
  • Future P/E36.71
  • EPS (ttm)-3.06
  • EPS growth next 5 years—

As of Nov 5, 2026